Mizuho says shares of Wave Life Sciences (WVE) should not have traded down yesterday on the STAT article suggesting suggesting the FDA had been leaning against accelerated approval for Sarepta’s (SRPT) SRP-9001 gene therapy for Duchenne muscular dystrophy. The news should not really change WVE-N531’s potential for accelerated approval going forward, the analyst tells investors in a research note. The firm says WVE-N531 aims to build regular, full-length dystrophin protein, versus micro dystrophin for SRP-9001, which as a surrogate endpoint for clinical improvement has several pieces of data to back it up. It keeps a Buy rating on Wave Life with a $13 price target, saying the pullback yesterday "makes no sense."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WVE:
- Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
- Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Wave Life Sciences expects cash to fund operations into 2025
- Wave Life Sciences reports Q4 EPS (47c), consensus (41c)
- Wave Life considers direct SVB exposure ‘immaterial’